Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Post by SanFrancisco99on May 08, 2014 10:07am

409 Views

Post# 22538070

PHOTO OF NEW BUILDING - STUNNING REALLY

Here is final proof that you guys are really, really off-base about the office move. Check out this photo of the stunning new building that Zenith and Resverlogix have moved into. This is obviously a first-class "Class A" office space, located right next to a major university campus.

LINK: https://www.gwlraleasing.com/building.php?building=westmount-corporate-campus-building-4

A photograph says it all. This is clearly a company with big plans for expansaion.

Bullboard Posts

Southern Ontario mineral processing operation receives green fund support